The effect of a new direct Factor Xa inhibitor on human osteoblasts: an in-vitro study comparing the effect of rivaroxaban with enoxaparin

BACKGROUND: Current treatments for the prevention of thromboembolism include heparin and low-molecular weight heparins (LMWHs). A number of studies have suggested that long term administration of these drugs may adversely affect osteoblasts and therefore, bone metabolism. Xarelto™ (Rivaroxaban) is a...

Descripción completa

Detalles Bibliográficos
Autores principales: Solayar, Gandhi N, Walsh, Pauline M, Mulhall, Kevin J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3215189/
https://www.ncbi.nlm.nih.gov/pubmed/22035050
http://dx.doi.org/10.1186/1471-2474-12-247

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3215189/
https://www.ncbi.nlm.nih.gov/pubmed/22035050
http://dx.doi.org/10.1186/1471-2474-12-247

Ejemplares similares